Title:Association of SARS-CoV-2 Infection and Triple Negative Breast Cancer
(TNBC) A Computational Illustrative Study
Volume: 20
Issue: 8
Author(s): A. M. Hima Vyshnavi and P. K. Krishnan Namboori*
Affiliation:
- AMMAS Research Lab, Computational Chemistry Group (CCG), Amrita School of Engineering, Amrita Vishwa
Vidyapeetham, Coimbatore, India
Keywords:
COVID 19, SARS-CoV-2, BRCA, TNBC, biomolecular networking, molecular dynamic.
Abstract:
Background: Anticipating the correlation between SARS-CoV-2 infection and ‘triplenegative
breast cancer (TNBC)’ remains challenging. It has been reported that people currently
diagnosed with cancer have a higher risk of severe complications if they are affected by the viral
infection. Cancer treatments, including chemotherapy, targeted therapies, and immunotherapy, may
weaken the immune system and possibly cause critical lung damage and breathing problems. Special
attention must be paid to the ‘comorbidity condition’ while estimating the risk of severe SARSCoV-
2 infection in TNBC patients. Hence the work aims to study the correlation between triplenegative
breast cancer (TNBC) and SARS-CoV-2 using biomolecular networking.
Methods: The genes associated with SARS CoV-2 have been collected from curated data in Bio-
GRID. TNBC-related genes have been collected from expression profiles. Molecular networking
has generated a Protein-Protein Interaction (PPI) network and a Protein-Drug Interaction (PDI) network.
The network results were further evaluated through molecular docking studies followed by
molecular dynamic simulation.
Results: The genetic correlation of TNBC and SARS-Cov-2 has been observed from the combined
PPI of their proteins. The drugs interacting with the disease's closely associated genes have been
identified. The docking and simulation study showed that anti-TNBC and anti-viral drugs interact
with these associated targets, suggesting their influence in inhibiting both the disease mutations.
Conclusion: The study suggests a slight influence of SARS-CoV-2 viral infection on Triple Negative
Breast Cancer. Few anticancer drugs such as Lapatinib, Docetaxel and Paclitaxel are found to
inhibit both TNBC and viral mutations. The computational studies suggest these molecules are also
useful for TNBC patients to control SARS-CoV-2 infection.